These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1012 related items for PubMed ID: 15118656

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 5. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 6. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 7. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun 01; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 8. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2006 Apr 01; 163(7):589-99. PubMed ID: 16484450
    [Abstract] [Full Text] [Related]

  • 9. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S.
    Climacteric; 2003 Dec 01; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?].
    Gaspard U.
    Bull Mem Acad R Med Belg; 2003 Dec 01; 158(1-2):133-41; discussion 141-5. PubMed ID: 12852099
    [Abstract] [Full Text] [Related]

  • 12. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2005 Sep 01; 162(5):404-14. PubMed ID: 16033876
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM, Fini M.
    Int J Fertil Womens Med; 2001 Sep 01; 46(5):248-56. PubMed ID: 11720197
    [Abstract] [Full Text] [Related]

  • 15. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.
    Maturitas; 2006 Sep 20; 55(2):103-15. PubMed ID: 16815651
    [Abstract] [Full Text] [Related]

  • 16. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Bittner V.
    Expert Opin Pharmacother; 2009 Sep 20; 10(13):2041-53. PubMed ID: 19563274
    [Abstract] [Full Text] [Related]

  • 17. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD.
    Ann N Y Acad Sci; 2005 Jun 20; 1052():57-74. PubMed ID: 16024751
    [Abstract] [Full Text] [Related]

  • 18. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS, Women's Health Initiative Mammogram Density Study Investigators.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1366-76. PubMed ID: 16174858
    [Abstract] [Full Text] [Related]

  • 19. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA, Blake JM, Crosignani PG.
    Hum Reprod Update; 2005 Sep 21; 11(6):545-60. PubMed ID: 16150813
    [Abstract] [Full Text] [Related]

  • 20. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.
    J Steroid Biochem Mol Biol; 2014 Jul 21; 142():4-11. PubMed ID: 24172877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.